These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33322052)
21. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
22. Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease. Moovarkumudalvan B; Geethakumari AM; Ramadoss R; Biswas KH; Mifsud B Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551182 [TBL] [Abstract][Full Text] [Related]
23. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701 [TBL] [Abstract][Full Text] [Related]
24. Docking Paradigm in Drug Design. Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135 [TBL] [Abstract][Full Text] [Related]
26. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease. Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115 [TBL] [Abstract][Full Text] [Related]
27. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2. Yassine R; Makrem M; Farhat F Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259 [TBL] [Abstract][Full Text] [Related]
28. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
29. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646 [TBL] [Abstract][Full Text] [Related]
31. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease. Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345 [TBL] [Abstract][Full Text] [Related]
32. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
33. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681 [TBL] [Abstract][Full Text] [Related]
35. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
36. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
37. Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its M Potshangbam AM; Nongdam P; Kumar AK; Rathore RS Curr Pharm Biotechnol; 2021; 22(15):2054-2070. PubMed ID: 33504301 [TBL] [Abstract][Full Text] [Related]
38. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease. Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750 [TBL] [Abstract][Full Text] [Related]
39. Identification of Main Protease of Coronavirus SARS-CoV-2 (M Elekofehinti OO; Iwaloye O; Famusiwa CD; Akinseye O; Rocha JBT Curr Drug Discov Technol; 2021; 18(5):e17092020186048. PubMed ID: 32957889 [TBL] [Abstract][Full Text] [Related]
40. Apigenin analogues as SARS-CoV-2 main protease inhibitors: Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]